What one share of Voyager Therapeutics holds
We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS.
Voyager Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.58 |
|---|---|
| Profit | −$1.81 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.04 |
| Cash and investments | $2.43 |
| Book value | $2.52 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.56 | −$1.59 | $0.20 | −$1.88 | — | $5.31 |
| 2017 | $0.38 | −$2.64 | $0.15 | −$2.44 | — | $4.25 |
| 2018 | $0.24 | −$2.75 | $0.13 | −$0.63 | $0.00 | $1.44 |
| 2019 | $2.91 | −$1.21 | $0.21 | $1.14 | $0.00 | $2.70 |
| 2020 | $4.58 | $0.98 | $0.32 | −$2.91 | $0.00 | $4.13 |
| 2021 | $0.99 | −$1.89 | $0.04 | −$1.46 | $0.00 | $2.51 |
| 2022 | $1.07 | −$1.21 | $0.06 | −$0.39 | — | $1.53 |
| 2023 | $5.61 | $2.97 | $0.07 | $1.68 | — | $5.37 |
| 2024 | $1.39 | −$1.13 | $0.06 | −$0.33 | — | $5.48 |
| 2025 | $0.69 | −$2.04 | $0.04 | −$2.30 | — | $3.32 |
Common questions about Voyager Therapeutics
How much does one share of Voyager Therapeutics earn?
Over the last 12 months, Voyager Therapeutics lost $1.81 for each share on $0.58 of sales.
Does Voyager Therapeutics pay a dividend?
Voyager Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Voyager Therapeutics’s book value per share?
Voyager Therapeutics’s book value is $2.52 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Voyager Therapeutics have?
Each share of Voyager Therapeutics has $2.43 of cash and investments, as of June 30, 2026.
What is Voyager Therapeutics’s free cash flow per share?
−$2.04 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Voyager Therapeutics bought back shares?
Voyager Therapeutics’s share count rose about 132% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.